#Global Trends – Page 8 – HEALTHCARE INSIGHTS

Key Development Basel-headquartered generic and biosimilar pharmaceuticals leader Sandoz Group AG has formally entered into definitive settlement agreements totaling approximately... Read more

Tag: #Global Trends

Historic Vaccine Milestone: US FDA Grants Approval for Moderna’s mFLUSIVA® – The World’s First mRNA-Based Seasonal Influenza Vaccine

Outbreak Diagnostic Response: Roche Launches Two Novel PCR Cyclospora Test Panels as U.S. Foodborne Outbreak Escalates to Record Levels

HIV & PrEP Commercial Acceleration: Gilead Sciences Outperforms Q2 2026 Revenue Estimates at $7.8 Billion, Offsetting One-Time M&A Charges

Anti-Obesity Franchise Market Dynamics: Novo Nordisk Raises 2026 Outlook, Yet Shares Fall 6% as Oral Wegovy Sales Miss Consensus and CagriSema Trial Disappoints

Post-COVID Restructuring Matrix: Pfizer Beats Q2 2026 Earnings Expectations, Targets Additional $2.5 Billion Cost Cuts, and Shifts M&A Strategy to Bolt-On Deals

Resolving Legacy Generic Price-Fixing Exposure: Sandoz Agrees to $480 Million Settlements to Conclude All US Federal, State, and Class-Action Antitrust Claims

Targeted Radiopharmaceuticals Expansion: Ratio Therapeutics Secures $70 Million Series C Financing Backed by Eli Lilly and Bristol Myers Squibb

Life Sciences Cyber Crisis: Amgen Suffers Third-Party Cloud Breach, Exposing Protected Patient Health Information and Proprietary R&D Data

Next-Gen Obesity Therapeutics: Eli Lilly Launches Early Access Program for Experimental Triple-Agonist Retatrutide Ahead of FDA Submission

Facebook

Map

Online Members